# Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

> **NCT02596334** · PHASE3 · TERMINATED · sponsor: **Centre Hospitalier Régional d'Orléans** · enrollment: 158 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** dolutegravir 50mg +abacavir 600mg +lamivudine 300mg
- **DRUG:** dolutegravir

## Key facts

- **NCT ID:** NCT02596334
- **Lead sponsor:** Centre Hospitalier Régional d'Orléans
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-23
- **Primary completion:** 2017-06-23
- **Final completion:** 2018-06-23
- **Target enrollment:** 158 (ACTUAL)
- **Why stopped:** 5 patients on tivicay had virological failure
- **Last updated:** 2018-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596334, "Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02596334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*